US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Milei Threatens Falkland Oil Firms With Sanctions 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Rejects Apple Trade Secret Theft Claims 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Add as a preferred source on Google
BASKING RIDGE, N.J., March 08, 2018 -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, today announces that management will be presenting at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) taking place March 15-17, 2018 at the Intercontinental Hotel in Hangzhou, China.
David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present a company overview on Friday, March 16, 2018 at 8:30 a.m. CST.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial. CLBS14, CD34 cell therapy intended as a treatment for coronary microvascular dysfunction and refractory angina, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is formulated specifically for intramuscular administration for the treatment of lower extremity ischemia. A phase 2 study of CLBS12 as a treatment for critical limb ischemia is enrolling in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations. For more information about Caladrius please visit www.caladrius.com.
Contacts:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: [email protected]
LHA Investor Relations
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777
Email: [email protected]
